Monday 13 October 2025
Home      All news      Contact us      RSS     
scmp - 7 month ago

After China probe, is AstraZeneca’s new US$2.5 billion plan a blueprint for foreign firms?

British-Swedish drug maker has gone from Beijing’s scrutiny to its praise, hailed as a sign of doing business in China.


Latest News
Hashtags:   

After

 | 

China

 | 

probe

 | 

AstraZeneca

 | 

billion

 | 

blueprint

 | 

foreign

 | 

firms

 | 

Sources